Puma Biotechnology, Inc.

NASDAQ:PBYI

Biotechnology

Healthcare
$7.22 +2.21%

+$0.16 today

Market cap
$373.26M
Beta
1.21
P/E (TTM)
15.4
EPS (TTM)
$0.48
52W Low $3.03High $7.90

Volume 0.45M

Average 0.26M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

$41.80M

FY 2025 · Annual

+7.4% YoY

Investing Cash Flow

-$36.19M

FY 2025 · Annual

Financing Cash Flow

-$45.20M

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(29.13M)2K21.59M30.28M31.11M
Depreciation & Amortization11.31M9.84M11.52M11.52M10.94M
Deferred Income Tax000(7.08M)3.25M
Stock-Based Compensation32.63M11.83M10.25M8.25M6.94M
Change in Working Capital(1.31M)(44.5M)(17.85M)(3.54M)(10.08M)
Accounts Receivables(5.98M)(7.82M)(8.37M)16.35M(21.28M)
Inventory(3.66M)2.58M(2.55M)(1.64M)3.21M
Accounts Payables(902K)(4.73M)449K(1.38M)(453K)
Other Working Capital9.23M(34.52M)(7.38M)(16.86M)8.45M
Other Non-Cash Items7.15M7M1.51M(519K)(358K)
Operating Cash Flow20.65M(15.83M)27.01M38.92M41.8M
Capital Expenditures0(7M)(12.64M)(56K)(71K)
Acquisitions (Net)00000
Purchases of Investments(38.07M)(4.84M)(23.81M)(76.23M)(108.14M)
Sales of Investments27.19M18.94M17.33M55.85M72.02M
Other Investing Activities00(12.5M)00
Investing Cash Flow(10.88M)7.1M(19.13M)(20.44M)(36.19M)
Debt Repayment(1.5M)00(33.33M)(44.44M)
Common Stock Issued012.5M0150K130K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(30.43M)(277K)0(666K)(888K)
Financing Cash Flow(31.93M)12.22M0(33.85M)(45.2M)
Effect of Forex Changes00000
Net Change in Cash(22.16M)3.5M7.88M(15.37M)(39.58M)
Free Cash Flow20.65M(22.83M)14.37M38.86M41.73M

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income$31.1M
+ D&A$10.9M
+ Stock-Based Comp$6.9M
+ Deferred Tax$3.2M
- Working Capital-$10.1M
- Other Non-Cash-$358.0K
= Operating Cash Flow$41.8M
- Capex-$71.0K
= Free Cash Flow$41.7M

Analysis

FY2025 free cash flow is $41.7M. FCF conversion is 134.1% of net income. Operating cash flow was $41.8M, with capex of -$71.0K. The largest bridge item is D&A at $10.9M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 13, 2026
10-QQuarterly reportNov 9, 2026
8-KCurrent reportNov 5, 2026
SC 13D/ASC 13D/A filingOct 6, 2026
4Statement of changes in beneficial ownershipSep 16, 2026

Does PBYI generate free cash flow?

Puma Biotechnology, Inc. (PBYI) generated $41.73M of free cash flow in fiscal 2025.

How much operating cash flow does PBYI produce?

Operating cash flow was $41.80M, before capital expenditures of $71,000.00.